Results 11 to 20 of about 11,328,563 (174)

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. [PDF]

Brain, 2023
AbstractExcess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer’s disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target amyloid-β and have identified MRI signal abnormalities called amyloid-related imaging ...
Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A.   +5 more
europepmc   +8 more sources

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease.

JAMA Neurol
ImportanceData from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.ObjectivesTo describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).Design, Setting,
Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R.   +16 more
europepmc   +6 more sources

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
Introduction Amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) are commonly observed with anti‐amyloid therapies in Alzheimer's disease.
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, Carsten Hofmann, Dominik Lott, Szofia Bullain, Paul Delmar, Gregory Klein, Marco Lyons, Fabrizio Piazza, Roxana O. Carare, Norman A. Mazer   +11 more
doaj   +2 more sources

Validation of 3‐ and 5‐point severity scales to assess ARIA‐E

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
INTRODUCTION Anti‐amyloid‐β (Aβ) monoclonal antibodies (mAbs) offer the promise of disease modification and are emerging treatment options in Alzheimer's disease.
Luc Bracoud, Gregory Klein, Marco Lyons, Marzia A. Scelsi, Jakub Wojtowicz, Szofia Bullain, Derk Purcell, Jochen B. Fiebach, Jerome Barakos, Joyce Suhy   +9 more
doaj   +2 more sources

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques.
Lawrence S. Honig, Jerome Barakos, Shobha Dhadda, Michio Kanekiyo, Larisa Reyderman, Michael Irizarry, Lynn D. Kramer, Chad J. Swanson, Marwan Sabbagh   +8 more
doaj   +2 more sources

From Lesion to Decision: AI for ARIA Detection and Predictive Imaging in Alzheimer’s Disease

Biomedicines
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with anti-amyloid monoclonal antibodies (MABs) marking a significant advance as the first disease-modifying therapies. Their use, however, is limited by amyloid-related
Rafail C. Christodoulou, Platon S. Papageorgiou, Maria Daniela Sarquis, Ludwing Rivera, Celimar Morales Gonzalez, Daniel Eller, Gipsany Rivera, Vasileia Petrou, Georgios Vamvouras, Evros Vassiliou, Sokratis G. Papageorgiou, Michalis F. Georgiou   +11 more
doaj   +2 more sources

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Scientific Reports
Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with edema (ARIA-E). We
Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou, Patrik Nygren, Nicolas Fritz, Olof Zachrisson, Adeline Rachalski, Anne-Sophie Svensson, Emily Button, Giacomo Dentoni, Gunilla Osswald, Lars Lannfelt, Christer Möller   +12 more
doaj   +2 more sources

Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center. [PDF]

J Prev Alzheimers Dis
: IMPORTANCE: Predictors of decline and of amyloid-related imaging abnormalities (ARIA) during anti-amyloid β therapy in routine care are undefined. OBJECTIVE: To identify baseline predictors of cognitive, functional, and safety outcomes. DESIGN, SETTING,
Kujuro Y, Saito M, Maruko M, Kamiyama K, Nakano A, Qian E, Okamura T, Ito D, Kageyama T, Sugiyama I, Ishihara E, Kuwahara T, Moritani K, Katai H, Hattori H.   +14 more
europepmc   +2 more sources

Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab. [PDF]

Alzheimers Dement (Amst)
INTRODUCTION Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons.
Hakim R, Harris K, Merrill L, Falk-Vargas A, Whalen E, Xia T, Ochoa O, Hunter D, Schulz PE.   +8 more
europepmc   +2 more sources

Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer's Disease. [PDF]

Dtsch Arztebl Int
Vöglein J, Levin J, Brendel M.
europepmc   +2 more sources